Legal & General Group Plc Has $16.07 Million Holdings in Masimo Co. (NASDAQ:MASI)

Legal & General Group Plc lowered its holdings in shares of Masimo Co. (NASDAQ:MASI - Free Report) by 1.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 97,187 shares of the medical equipment provider's stock after selling 1,683 shares during the period. Legal & General Group Plc owned approximately 0.18% of Masimo worth $16,065,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of MASI. FMR LLC boosted its stake in shares of Masimo by 19.8% during the 4th quarter. FMR LLC now owns 8,097,454 shares of the medical equipment provider's stock worth $1,338,509,000 after acquiring an additional 1,340,836 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Masimo by 119.0% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,735,167 shares of the medical equipment provider's stock valued at $286,823,000 after purchasing an additional 943,001 shares during the period. Alliancebernstein L.P. increased its stake in Masimo by 1,276.9% in the 4th quarter. Alliancebernstein L.P. now owns 947,391 shares of the medical equipment provider's stock worth $156,604,000 after purchasing an additional 878,587 shares in the last quarter. Corient Private Wealth LLC raised its holdings in Masimo by 8,847.1% during the 4th quarter. Corient Private Wealth LLC now owns 347,683 shares of the medical equipment provider's stock worth $57,472,000 after buying an additional 343,797 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in Masimo during the fourth quarter valued at about $33,716,000. Institutional investors own 85.96% of the company's stock.

Masimo Stock Up 0.3 %

Shares of MASI traded up $0.47 during midday trading on Friday, reaching $152.15. 457,368 shares of the stock were exchanged, compared to its average volume of 658,313. The company has a market cap of $8.22 billion, a price-to-earnings ratio of 104.93 and a beta of 1.28. The firm has a 50 day simple moving average of $168.04 and a 200-day simple moving average of $164.70. Masimo Co. has a 12-month low of $101.61 and a 12-month high of $194.88. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50.

Masimo (NASDAQ:MASI - Get Free Report) last posted its earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.42 by $0.38. The firm had revenue of $600.70 million during the quarter, compared to analysts' expectations of $593.35 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. Research analysts forecast that Masimo Co. will post 4.1 EPS for the current year.

Analyst Ratings Changes

MASI has been the topic of a number of recent analyst reports. Needham & Company LLC restated a "hold" rating on shares of Masimo in a report on Thursday, April 10th. Raymond James upped their price target on Masimo from $170.00 to $194.00 and gave the company an "outperform" rating in a research report on Friday, December 27th. Piper Sandler raised their price objective on Masimo from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Finally, Wells Fargo & Company upped their target price on Masimo from $193.00 to $205.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Masimo currently has a consensus rating of "Moderate Buy" and an average target price of $194.80.

Insider Activity at Masimo

In other news, Director Craig B. Reynolds sold 2,053 shares of the stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $166.13, for a total value of $341,064.89. Following the completion of the sale, the director now directly owns 16,581 shares of the company's stock, valued at approximately $2,754,601.53. This represents a 11.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Bilal Muhsin sold 30,000 shares of the business's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the transaction, the chief operating officer now directly owns 24,172 shares in the company, valued at $4,048,568.28. This trade represents a 55.38 % decrease in their position. The disclosure for this sale can be found here. 16.90% of the stock is currently owned by company insiders.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.